Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $37.56 Average Price Target from Brokerages

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the ten analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $37.56.

Several equities analysts have issued reports on the stock. JMP Securities decreased their price objective on shares of Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 7th. Royal Bank Of Canada decreased their price objective on shares of Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. HC Wainwright restated a "buy" rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. Needham & Company LLC restated a "buy" rating and issued a $36.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday, May 20th. Finally, The Goldman Sachs Group decreased their price objective on shares of Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th.

Viridian Therapeutics Trading Up 1.0%

NASDAQ VRDN traded up $0.16 on Monday, reaching $16.05. The stock had a trading volume of 807,335 shares, compared to its average volume of 1,151,772. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of -4.17 and a beta of 0.39. The company has a quick ratio of 19.49, a current ratio of 19.49 and a debt-to-equity ratio of 0.05. Viridian Therapeutics has a 12-month low of $9.90 and a 12-month high of $27.20. The stock has a fifty day moving average price of $14.11 and a two-hundred day moving average price of $15.48.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.87) EPS for the quarter, topping analysts' consensus estimates of ($0.95) by $0.08. The firm had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.16 million. Viridian Therapeutics had a negative net margin of 102,092.39% and a negative return on equity of 70.61%. The company's revenue was up .0% on a year-over-year basis. As a group, sell-side analysts forecast that Viridian Therapeutics will post -4.03 EPS for the current fiscal year.

Hedge Funds Weigh In On Viridian Therapeutics

A number of hedge funds have recently made changes to their positions in VRDN. Foresite Capital Management VI LLC purchased a new stake in Viridian Therapeutics during the 4th quarter worth $38,000. Amalgamated Bank increased its stake in Viridian Therapeutics by 49.7% during the 1st quarter. Amalgamated Bank now owns 2,531 shares of the company's stock worth $34,000 after buying an additional 840 shares during the period. AlphaQuest LLC increased its stake in Viridian Therapeutics by 119.0% during the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock worth $54,000 after buying an additional 1,519 shares during the period. Summit Investment Advisors Inc. increased its stake in Viridian Therapeutics by 24.7% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock worth $147,000 after buying an additional 1,516 shares during the period. Finally, GAMMA Investing LLC increased its position in shares of Viridian Therapeutics by 3,892.9% in the 1st quarter. GAMMA Investing LLC now owns 8,425 shares of the company's stock worth $114,000 after purchasing an additional 8,214 shares during the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.